Can you spot the image with the faked aortic dissection?
Korean researchers tested the ability of radiologists to spot CT images altered with commercially available software to introduce pathology and found that their skill at doing so is no more certain than a coin flip.
Korean researchers tested the ability of radiologists to spot CT images altered with commercially available software to introduce pathology and found that their skill at doing so is no more certain than a coin flip. Researchers from the Catholic University of Korea designed a test to find out how well 17 attending radiologists and 13 residents could spot images with faked and real pathology in a set of 10 images. After being told that some of the images were digitally altered, the attending radiologists were able to spot the five fakes only 51.8% of the time. Residents spotted the fakes just 47.7% of the time. “The recognition of retouched images was like coin flipping,” said Catholic University’s Hee Jae Chang, who presented the study at the 2009 RSNA meeting. For more details about the study (abstract No. SSQ10-04), along with comments from the audience and moderators, go to Diagnostic Imaging’s RSNA 2009 conference reporter at diagnosticimaging.com. The article was posted Dec. 4. And, so you know, the one on the bottom is the altered image.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
FDA Issues Expanded Pediatric Approval of MRI Contrast Agent for Lung Ventilation Assessment
June 2nd 2025Previously approved for MRI lung ventilation evaluation in adults and children 12 and older, the hyperpolarized contrast agent Xenoview can now be utilized for pediatric patients six years and older.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
